BMS-986165, an Oral, Selective TYK2 Inhibitor, in the Treatment of Moderate to Severe Psoriasis as Assessed by the Static Physician's Global Assessment (sPGA)/Body Surface Area (BSA) Composite Tool (sPGAxBSA), a Clinically Useful Alternative to PASI

Main Article Content

Alice B Gottlieb
Bruce Strober
Diamant Tha?i
Kenneth Gordon
Sundeep Kundu
Renata Kisa
Lan Wei
Subhashis Banerjee
Joseph Merola

Keywords

Psoriasis, Tyrosine Kinase Inhibitor

Abstract

Abstract not available.

References

1. Spuls PI et al. J Invest Dermatol. 2010;130:933-943.

2. Walsh JA et al. J Am Acad Dermatol. 2013;69:931-937.

3. Duffin KC et al. J Drugs Dermatol. 2017;16:147-153.

4. Gottlieb AB et al. Dermatology. 2019;235:348-354.

5. Merola JF et al. J Invest Dermatol. 2018;138:1955-1961.

6. Watford WT et al. Immunol Rev. 2004;202:139-156.

7. Tokarski JS et al. J Biol Chem. 2015;290:11061-11074.

8. Volpe E et al. Nat Immunol. 2008;9:650-657.

9. Geremia A et al. J Exp Med. 2011;208:1127-1133.

10. Tucci M et al. Clin Exp Immunol. 2008;154:247-254.

11. Gillooly K et al. Arthritis Rheumatol. 2016;68(suppl10):abstract 11L.

12. Papp K et al. N Engl J Med. 2018;379:1313-1321.

13. Gottlieb AB et al. J Am Acad Dermatol. 2017;77:1178-1180.

Article Sidebar

Poster PDF
Published
Sep 2, 2020
DOI https://doi.org/10.25251/skin.4.supp.29

Article Details

How to Cite
Gottlieb, A. B., Strober, B., Tha?i, D., Gordon, K., Kundu, S., Kisa, R., Wei, L., Banerjee, S., & Merola, J. (2020). BMS-986165, an Oral, Selective TYK2 Inhibitor, in the Treatment of Moderate to Severe Psoriasis as Assessed by the Static Physician’s Global Assessment (sPGA)/Body Surface Area (BSA) Composite Tool (sPGAxBSA), a Clinically Useful Alternative to PASI. SKIN The Journal of Cutaneous Medicine, 4(5), s29. https://doi.org/10.25251/skin.4.supp.29
Issue
Vol. 4 No. 5 (2020): September Issue & Poster Presentations (FCPANP20® Dermatology Conference)
Section
Poster Presentations from FCPANP20 Clinical Conference®: Psoriasis
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by  the following user license:
 

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation. 

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)

1 2 3 4 5 6 7 8 > >>